Evidence map›Paper›PMID 36419346›Full record

ArticleJournal of the International AIDS Society2022

Protecting the gains: analysis of HIV treatment and service delivery programme data and interventions implemented in 19 African countries during COVID-19.

Pamela J Bachanas, Helen M Chun, Neha Mehta, John Aberle-Grasse, KaeAnne Parris, Michelle Williams Sherlock, Spencer Lloyd, Clement Zeh, Daphne K Makwepa, Max L Kapanda and 38 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors at 20 institutions in 23 countries.

Pamela J BachanasDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-9408-9904
Helen M ChunDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Neha MehtaDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
John Aberle-GrasseDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
KaeAnne ParrisDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Michelle Williams SherlockDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Spencer LloydDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Clement ZehDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Daphne K MakwepaDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Gaborone, Botswana.
Max L KapandaNational ART Program, Ministry of Health and Wellness, Gaborone, Botswana.
Emily Kainne DokuboDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Yaounde, Cameroon.
Leonard BononoNational AIDS Control Committee, Ministry of Public Health, Yaounde, Cameroon.
Shirish BalachandraDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Abidjan, Cote d' Ivoire.
Eboi EhuiNational AIDS Control Program, Ministry of Health and Public Hygiene, Abidjan, Cote d' Ivoire.
Peter FonjungoDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of the Congo.
Aimé M NkosoMinistry of Health, Kinshasa, Democratic Republic of Congo.
Sikhathele MazibukoDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Mbabane, Eswatini.
Velephi N OkelloHealth Services - Clinical, Ministry of Health, Mbabane, Eswatini.
Fana TeferaDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Addis Ababa, Ethiopia.
Mirtie GetachewDisease Prevention and Control Directorate, Ministry of Health, Addis Ababa, Ethiopia.
Elizabeth M KatikuDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Nairobi, Kenya.
Andrew MulwaPreventive and Promotive Health, Ministry of Health, Nairobi, Kenya.
Fred M AsiimweDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Maseru, Lesotho.
Tapiwa F TarumbiswaMinistry of Health, Maseru, Lesotho.
Andrew F AuldDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Lilongwe, Malawi.
Rose NyirendaMinistry of Health, Lilongwe, Malawi.
Alzira P Dos Santos De LouvadoDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Maputo, Mozambique.
Irenio GasparHIV Program, Ministry of Health, Maputo, Mozambique.
Steven Y HongDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Windhoek, Namibia.
Laimi AshipalaHIV/STI Sub-Division, Directorate Special Programmes, Ministry of Health and Social Services, Windhoek, Namibia.
Christopher ObanubiDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Abuja, Nigeria.
Akudo IkpeazuNational AIDS/STI Control Programme, Federal Ministry of Health, Abuja, Nigeria.
Canisious MusoniDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Kigali, Rwanda.
Emmanuel YobokaMinistry of Health, Kigali, Rwanda.
Simangele MthethwaDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Pretoria, South Africa.
Zukiswa PininiHIV, AIDS & STIs Cluster, National Department of Health, Pretoria, South Africa.
Sudhir BungaDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Juba, South Sudan.
John RumunuPreventive Health Services, Ministry of Health, Juba, Republic South Sudan.
Daniel J MagesaDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.
Beatrice MutayobaMinistry of Health, Dar es Salaam, Tanzania.
Lisa J NelsonDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Kampala, Uganda.
Cordelia KatureebeMinistry of Health, Kampala, Uganda.
Simon AgoloryDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Lusaka, Zambia.ORCID 0000-0001-5023-5754
Lloyd B MulengaMinistry of Health, Lusaka, Zambia.
Ponesai NyikaDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Harare, Zimbabwe.
Owen MugurungiMinistry of Health, Harare, Zimbabwe.
Tedd EllerbrockDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Kiren MitrukaDivision of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Centers for Disease Control and Prevention · UGCenters for Disease Control and Prevention · USDepartment of Health · ZAFederal Ministry of Health · NGFederal Ministry of Health · SDGovernment of Ethiopia · ETInstitut National d’Hygiène Publique · CIMinistry of Health · ZMMinistry of Health · UGMinistry of Health · BWMinistry of Health · KEMinistry of Health · SZMinistry of Health · MWMinistry of Health · RWMinistry of Health · MZMinistry of Health · LSMinistry of Health and Child Welfare · ZWMinistry of Health and Social Services · NAMinistry of Health and Social Welfare · TZMinistry of Public Health · CD

Funding

PEPFAR
6 · The paper itself

Abstract

introductionThe potential disruption in antiretroviral therapy (ART) services in Africa at the start of the COVID-19 pandemic raised concern for increased morbidity and mortality among people living with HIV (PLHIV). We describe HIV treatment trends before and during the pandemic and interventions implemented to mitigate COVID-19 impact among countries supported by the US Centers for Disease Control and Prevention (CDC) through the President's Emergency Plan for AIDS Relief (PEPFAR).

methodsWe analysed quantitative and qualitative data reported by 10,387 PEPFAR-CDC-supported ART sites in 19 African countries between October 2019 and March 2021. Trends in PLHIV on ART, new ART initiations and treatment interruptions were assessed. Viral load coverage (testing of eligible PLHIV) and viral suppression were calculated at select time points. Qualitative data were analysed to summarize facility- and community-based interventions implemented to mitigate COVID-19.

resultsThe total number of PLHIV on ART increased quarterly from October 2019 (n = 7,540,592) to March 2021 (n = 8,513,572). The adult population (≥15 years) on ART increased by 14.0% (7,005,959-7,983,793), while the paediatric population (<15 years) on ART declined by 2.6% (333,178-324,441). However, the number of new ART initiations dropped between March 2020 and June 2020 by 23.4% for adults and 26.1% for children, with more rapid recovery in adults than children from September 2020 onwards. Viral load coverage increased slightly from April 2020 to March 2021 (75-78%) and viral load suppression increased from October 2019 to March 2021 (91-94%) among adults and children combined. The most reported interventions included multi-month dispensing (MMD) of ART, community service delivery expansion, and technology and virtual platforms use for client engagement and site-level monitoring. MMD of ≥3 months increased from 52% in October 2019 to 78% of PLHIV ≥ age 15 on ART in March 2021.

conclusionsWith an overall increase in the number of people on ART, HIV programmes proved to be resilient, mitigating the impact of COVID-19. However, the decline in the number of children on ART warrants urgent investigation and interventions to prevent further losses experienced during the COVID-19 pandemic and future public health emergencies.

Indexed as

COVID-19HIV InfectionsAdolescentAdultAfricaAnti-Retroviral AgentsChildHumansPandemicsAnti-Retroviral AgentsCOVID-19differentiated careretentiontreatmenttreatment interruptionviral suppression

Identifiers

PMID36419346
PMCPMC9684677
OpenAlexW4309862706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.